Renal Cell Carcinoma Highlights From ESMO 2023 Renal Cell Carcinoma Highlights From ESMO 2023

Dr Brian Rini reviews key studies on renal cell carcinoma from ESMO 2023, including several LITESPARK trials examining belzutifan, and the RENOTORCH trial from China looking at a IO/TKI combination.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news